Saul Arteaga Cruz
Postdoctoral Scholar, General Surgery
Bio
I am an immunologist and postdoctoral scholar in the Department of Surgery at Stanford University, working in the laboratory of Dr. Alma-Martina Cepika. My research interests center on FOXP3+ regulatory T (Treg) cells and type 1 regulatory T (Tr1) cells in human cancer, particularly their roles in immune regulation within the tumor microenvironment.
My work combines studies of human tissues with advanced flow cytometry, functional immunology, and computational analysis to investigate Treg and Tr1 biology in cancer. I am interested in understanding how these populations shape antitumor immune responses and how this knowledge may inform cancer immunotherapy.
During my doctoral training at the National Autonomous University of Mexico (UNAM), I studied regulatory T cells, including Tr1 cells, and immune tolerance in transplantation. This background provides a foundation for my current work on immune regulation in human tumors.
Current Research and Scholarly Interests
My research in the Cepika laboratory centers on FOXP3+ regulatory T (Treg) cells and type 1 regulatory T (Tr1) cells in human tumors. I am interested in understanding their biology, function, and interactions with the tumor microenvironment, and how these populations shape antitumor immune responses.
I combine human tissue studies, advanced flow cytometry, functional assays, and analysis of single-cell and spatial data to investigate immune regulation in cancer. Building on my background in Treg and Tr1 biology in transplantation, my broader goal is to connect mechanistic insights with translational research that may inform cancer immunotherapy.
All Publications
-
Increased phenotypic and functional stability of human allospecific induced Tregs is associated with Vitamin C-mediated FOXP3 TSDR demethylation.
Frontiers in immunology
2026; 17: 1827886
Abstract
While numerous preclinical models emphasize the therapeutic promise of in vitro-induced Tregs (iTregs) for managing inflammatory diseases and promoting tolerance, their translation to clinical use is limited by concerns over phenotypic and functional instability, largely due to an epigenetic profile distinct from thymic Tregs.To address this, we generated and expanded iTregs in the presence of Vitamin C, known to activate TET enzymes that demethylate critical gene regions such as FOXP3. Antigen-specific Tregs were derived from allogeneic co-cultures of monocyte-derived dendritic cells and naïve T cells. After 7 days, allo-Tregs were isolated by FACS and further expanded for 3 weeks with IL-2, TGF-β, rapamycin, with or without Vitamin C supplementation.iTregs treated with Vitamin C displayed heightened FOXP3 expression and sustained high levels of suppressive markers (PD-L1, CD39, TIGIT, and CTLA-4), as well as chemokine receptors linked to allograft homing (CCR4, CCR5, and CXCR3). These cells also demonstrated enhanced allospecific suppression of CD4 + and CD8 + T cell proliferation, even in the presence of pro-inflammatory cytokines. Notably, this proinflammatory milieu did not trigger the production of intracellular cytokines IL-17 and IFN-γ by allo-iTregs, confirming their sustained phenotypic and functional stability. Advanced analysis demonstrated that allo-iTregs possess a unique profile, setting them apart from conventional T cells. Pyrosequencing of the FOXP3 TSDR revealed reduced CpG methylation in Vitamin C-treated iTregs (60.9% at day 21 and 43.5% at day 28) compared to untreated allo-iTregs (85.9% at day 21 and 80.5% at day 28) and naïve T cells (92.8%). In addition, transcriptomic analysis demonstrated that the core Treg transcriptional signature remained largely intact with Vitamin C treatment, irrespective of cytokine exposure, whereas the major transcriptional changes were associated with activation, proliferation, and cell cycle regulation.In summary, Vitamin C enhances both the phenotypic and functional stability of allospecific iTregs, even under proinflammatory conditions, correlating with increased TSDR demethylation, while preserving the transcription of key Treg genes. These results suggest that Vitamin C-treated allospecific iTregs are superior candidates for immunotherapy strategies to promote long-term tolerance in transplant recipients.
View details for DOI 10.3389/fimmu.2026.1827886
View details for PubMedID 42488647
View details for PubMedCentralID PMC13388274
-
CD25+CD27+CD70- alloantigen-specific Tregs: promising stable immunotherapy for transplantation.
Frontiers in immunology
2026; 17: 1789008
Abstract
The clinical translation of alloantigen-specific regulatory T cells (AS-Tregs) is constrained by their low frequency in peripheral blood, limited purity, and functional instability following prolonged ex vivo expansion. To address these hurdles, we developed a strategy to isolate and expand a functional CD25+CD27+CD70- AS-Treg population. Initially, Tregs were co-cultured with allogeneic dendritic cells in the presence of IL-15, IL-2, and retinoic acid. Proliferating CD25+CD27+CD70- AS-Tregs were subsequently FACS-sorted and expanded via polyclonal anti-CD3/CD28 stimulation with IL-15, IL-2, rapamycin, and TGF-β. Over three weeks, this protocol yielded a 434-fold expansion, achieving >95% purity (CD25+FOXP3+) while maintaining a substantial degree (>60%) of FOXP3-TSDR demethylation, a hallmark of stable Treg lineage commitment. The expanded CD27+ AS-Tregs exhibited a robust immunoregulatory phenotype, characterized by high expression of Helios, CTLA-4, and CD39, as well as chemokine receptors associated with allograft and lymphoid tissue homing (CXCR3, CCR4, and CCR7). Functionally, CD27+ AS-Tregs suppressed T cell proliferation in an antigen-specific manner, even after exposure to inflammatory cytokines, and showed a concentration-dependent chemotactic response to CXCL10 in vitro. In addition, these cells maintained lineage fidelity by lacking the production of inflammatory cytokines such as IFN-γ and IL-17A. Accordingly, transcriptional profiling by RNA sequencing confirmed the enrichment of immunoregulatory signatures and revealed minimal changes in gene expression when expanded Tregs were exposed to inflammatory conditions. Overall, our findings suggest that CD27+ AS-Tregs represent promising candidates for more stable, long-term Treg therapy to support transplant tolerance.
View details for DOI 10.3389/fimmu.2026.1789008
View details for PubMedID 42358982
View details for PubMedCentralID PMC13290811
-
Induced regulatory T cells as immunotherapy in allotransplantation and autoimmunity: challenges and opportunities.
Journal of leukocyte biology
2024; 116 (5): 947-965
Abstract
Regulatory T cells play a crucial role in the homeostasis of the immune response. Regulatory T cells are mainly generated in the thymus and are characterized by the expression of Foxp3, which is considered the regulatory T-cell master transcription factor. In addition, regulatory T cells can be induced from naive CD4+ T cells to express Foxp3 under specific conditions both in vivo (peripheral regulatory T cells) and in vitro (induced regulatory T cells). Both subsets of thymic regulatory T cells and peripheral regulatory T cells are necessary for the establishment of immune tolerance to self and non-self antigens. Although it has been postulated that induced regulatory T cells may be less stable compared to regulatory T cells, mainly due to epigenetic differences, accumulating evidence in animal models shows that induced regulatory T cells are stable in vivo and can be used for the treatment of inflammatory disorders, including autoimmune diseases and allogeneic transplant rejection. In this review, we describe the biological characteristics of induced regulatory T cells, as well as the key factors involved in induced regulatory T-cell transcriptional, metabolic, and epigenetic regulation, and discuss recent advances for de novo generation of stable regulatory T cells and their use as immunotherapeutic tools in different experimental models. Moreover, we discuss the challenges and considerations for the application of induced regulatory T cells in clinical trials and describe the new approaches proposed to achieve in vivo stability, including functional or metabolic reprogramming and epigenetic editing.
View details for DOI 10.1093/jleuko/qiae062
View details for PubMedID 38630873
-
Highly purified and functionally stable in vitro expanded allospecific Tr1 cells expressing immunosuppressive graft-homing receptors as new candidates for cell therapy in solid organ transplantation.
Frontiers in immunology
2023; 14: 1062456
Abstract
The development of new strategies based on the use of Tr1 cells has taken relevance to induce long-term tolerance, especially in the context of allogeneic stem cell transplantation. Although Tr1 cells are currently identified by the co-expression of CD49b and LAG-3 and high production of interleukin 10 (IL-10), recent studies have shown the need for a more exhaustive characterization, including co-inhibitory and chemokines receptors expression, to ensure bona fide Tr1 cells to be used as cell therapy in solid organ transplantation. Moreover, the proinflammatory environment induced by the allograft could affect the suppressive function of Treg cells, therefore stability of Tr1 cells needs to be further investigated. Here, we establish a new protocol that allows long-term in vitro expansion of highly purified expanded allospecific Tr1 (Exp-allo Tr1). Our expanded Tr1 cell population becomes highly enriched in IL-10 producers (> 90%) and maintains high expression of CD49b and LAG-3, as well as the co-inhibitory receptors PD-1, CTLA-4, TIM-3, TIGIT and CD39. Most importantly, high dimensional analysis of Exp-allo Tr1 demonstrated a specific expression profile that distinguishes them from activated conventional T cells (T conv), showing overexpression of IL-10, CD39, CTLA-4 and LAG-3. On the other hand, Exp-allo Tr1 expressed a chemokine receptor profile relevant for allograft homing and tolerance induction including CCR2, CCR4, CCR5 and CXCR3, but lower levels of CCR7. Interestingly, Exp-allo Tr1 efficiently suppressed allospecific but not third-party T cell responses even after being expanded in the presence of proinflammatory cytokines for two extra weeks, supporting their functional stability. In summary, we demonstrate for the first time that highly purified allospecific Tr1 (Allo Tr1) cells can be efficiently expanded maintaining a stable phenotype and suppressive function with homing potential to the allograft, so they may be considered as promising therapeutic tools for solid organ transplantation.
View details for DOI 10.3389/fimmu.2023.1062456
View details for PubMedID 36911743
View details for PubMedCentralID PMC9998667
-
Highly Purified Alloantigen-Specific Tregs From Healthy and Chronic Kidney Disease Patients Can Be Long-Term Expanded, Maintaining a Suppressive Phenotype and Function in the Presence of Inflammatory Cytokines.
Frontiers in immunology
2021; 12: 686530
Abstract
The adoptive transfer of alloantigen-specific regulatory T cells (alloTregs) has been proposed as a therapeutic alternative in kidney transplant recipients to the use of lifelong immunosuppressive drugs that cause serious side effects. However, the clinical application of alloTregs has been limited due to their low frequency in peripheral blood and the scarce development of efficient protocols to ensure their purity, expansion, and stability. Here, we describe a new experimental protocol that allows the long-term expansion of highly purified allospecific natural Tregs (nTregs) from both healthy controls and chronic kidney disease (CKD) patients, which maintain their phenotype and suppressive function under inflammatory conditions. Firstly, we co-cultured CellTrace Violet (CTV)-labeled Tregs from CKD patients or healthy individuals with allogeneic monocyte-derived dendritic cells in the presence of interleukin 2 (IL-2) and retinoic acid. Then, proliferating CD4+CD25hiCTV- Tregs (allospecific) were sorted by fluorescence-activated cell sorting (FACS) and polyclonally expanded with anti-CD3/CD28-coated beads in the presence of transforming growth factor beta (TGF-β), IL-2, and rapamycin. After 4 weeks, alloTregs were expanded up to 2,300 times the initial numbers with a purity of >95% (CD4+CD25hiFOXP3+). The resulting allospecific Tregs showed high expressions of CTLA-4, LAG-3, and CD39, indicative of a highly suppressive phenotype. Accordingly, expanded alloTregs efficiently suppressed T-cell proliferation in an antigen-specific manner, even in the presence of inflammatory cytokines (IFN-γ, IL-4, IL-6, or TNF-α). Unexpectedly, the long-term expansion resulted in an increased methylation of the specific demethylated region of Foxp3. Interestingly, alloTregs from both normal individuals and CKD patients maintained their immunosuppressive phenotype and function after being expanded for two additional weeks under an inflammatory microenvironment. Finally, phenotypic and functional evaluation of cryopreserved alloTregs demonstrated the feasibility of long-term storage and supports the potential use of this cellular product for personalized Treg therapy in transplanted patients.
View details for DOI 10.3389/fimmu.2021.686530
View details for PubMedID 34777330
View details for PubMedCentralID PMC8581357
-
Large-Scale Generation of Human Allospecific Induced Tregs With Functional Stability for Use in Immunotherapy in Transplantation.
Frontiers in immunology
2020; 11: 375
Abstract
Regulatory T cells play an important role in the control of autoimmune diseases and maintenance of tolerance. In the context of transplantation, regulatory T cells (Tregs) have been proposed as new therapeutic tools that may induce allospecific tolerance toward the graft, avoiding the side effects induced by generalized immunosuppressors. Although most clinical trials are based on the use of thymic Tregs in adoptive therapy, some reports suggest the potential use of in vitro induced Tregs (iTregs), based on their functional stability under inflammatory conditions, indicating an advantage in a setting of allograft rejection. The aim of this work was to generate and expand large numbers of allospecific Tregs that maintain stable suppressive function in the presence of pro-inflammatory cytokines. Dendritic cells were derived from monocytes isolated from healthy donors and were co-cultured with CTV-labeled naïve T cells from unrelated individuals, in the presence of TGF-β1, IL-2, and retinoic acid. After 7 days of co-culture, proliferating CD4+CD25++CTV- cells (allospecific iTregs) were sorted and polyclonally expanded for 6 weeks in the presence of TGF-β1, IL-2, and rapamycin. After 6 weeks of polyclonal activation, iTregs were expanded 230,000 times, giving rise to 4,600 million allospecific iTregs. Allospecific iTregs were able to specifically suppress the proliferation of autologous CD4+ and CD8+ T cells in response to the allo-MoDCs used for iTreg generation, but not to third-party allo-MoDCs. Importantly, 88.5% of the expanded cells were CD4+CD25+FOXP3+, expressed high levels of CCR4 and CXCR3, and maintained their phenotype and suppressive function in the presence of TNF-α and IL-6. Finally, analysis of the methylation status of the FOXP3 TSDR locus demonstrated a 40% demethylation in the purified allospecific iTreg, prior to the polyclonal expansion. Interestingly, the phenotype and suppressive activity of expanded allospecific iTregs were maintained after 6 weeks of expansion, despite an increase in the methylation status of the FOXP3 TSDR. In conclusion, this is the first report that demonstrates a large-scale generation of allospecific iTregs that preserve a stable phenotype and suppressor function in the presence of pro-inflammatory cytokines and pave the way for adoptive cell therapy with iTregs in transplanted patients.
View details for DOI 10.3389/fimmu.2020.00375
View details for PubMedID 32300340
View details for PubMedCentralID PMC7142244
-
Ex vivo expansion of regulatory T cells from long-term Belatacept-treated kidney transplant patients restores their phenotype and suppressive function but not their FOXP3 TSDR demethylation status.
Cellular immunology
2020; 348: 104044
Abstract
We recently reported that Tregs from long-term Belatacept-treated kidney transplant patients displayed an altered phenotype and impaired suppressive function compared to Tregs from healthy controls. However, it remains unknown whether ex vivo expansion of Tregs from patients who underwent long-term immunosuppression may be feasible to be used in their treatment. In this work, Tregs from Belatacept-treated patients were polyclonally expanded in vitro in the presence of rapamycin and IL-2. After four weeks of expansion, Tregs from patients expressed high levels of FOXP3, CD25, CTLA-4, Helios and CCR7, and showed strong suppressive activity, even in the presence of pro-inflammatory cytokines. However, FOXP3 TSDR demethylation remained lower in expanded Tregs from Belatacept-treated patients compared to healthy control Tregs. These data suggest that ex vivo expansion of Tregs from patients undergoing long-term immunosuppression may require the use of epigenetic modifying agents to stabilize FOXP3 expression to be considered as treatment in kidney transplant patients.
View details for DOI 10.1016/j.cellimm.2020.104044
View details for PubMedID 32005344